| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/29/2002 | US20020119930 Blocking endotoxins |
| 08/29/2002 | US20020119929 Fertility; genetic engineering |
| 08/29/2002 | US20020119928 Mixture of colostrum, lactoferrin, pectin and glucan |
| 08/29/2002 | US20020119927 Protein-protein interactions in neurodegenerative diseases |
| 08/29/2002 | US20020119926 Inhibitors of IAPP fibril formation and uses thereof |
| 08/29/2002 | US20020119924 Combination therapy using a TNF binding protein for treating TNF-mediated diseases |
| 08/29/2002 | US20020119923 Administering macrophage derived compound |
| 08/29/2002 | US20020119922 Peptides for inhibition of HIV infection |
| 08/29/2002 | US20020119921 Thrombospondin-2 and uses thereof |
| 08/29/2002 | US20020119920 Genetic engineering; diagnosis, therapy |
| 08/29/2002 | US20020119919 Nucleic acids, proteins, and antibodies |
| 08/29/2002 | US20020119918 Therapeutic uses of n-terminal bpi protein products in anca-positive patients |
| 08/29/2002 | US20020119917 Rheumatic disease |
| 08/29/2002 | US20020119915 Dietetics |
| 08/29/2002 | US20020119914 Topical applying; skin disorders |
| 08/29/2002 | US20020119913 61833, a novel human pyridoxyl-dependent decarboxylase family member and uses thereof |
| 08/29/2002 | US20020119910 Drug delivery |
| 08/29/2002 | US20020119566 Methods and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules |
| 08/29/2002 | US20020119554 Arginase II |
| 08/29/2002 | US20020119552 Human oncogene induced secreted protein I |
| 08/29/2002 | US20020119544 Genetic engineering |
| 08/29/2002 | US20020119541 Tumor suppressor CAR-1 |
| 08/29/2002 | US20020119539 Isolation of purified tgf -beta1 and tgf -beta2 from bone tissue |
| 08/29/2002 | US20020119528 Nucleotide sequences coding polypeptide for use inthe treatment of leukemia, tumors, infections, autoimmune disease, fibrosis, psoriasis and brain disorders |
| 08/29/2002 | US20020119522 Novel human ion channel-related proteins and polynucleotides encoding the same |
| 08/29/2002 | US20020119521 Expression vector or use as tools in gene therapy |
| 08/29/2002 | US20020119519 Nucleotide sequences coding preferential polyeptide for use in the treatment of cancer, kidney and respiratory disorders |
| 08/29/2002 | US20020119517 Detection of modulators of body weight; obtain cell samples, monitor expression of preferenial genes, incubate with modulators, compare to control, monitor adjustment in body weight |
| 08/29/2002 | US20020119512 Ups |
| 08/29/2002 | US20020119510 Enzymatic polypeptide for use in screening bactericides |
| 08/29/2002 | US20020119509 Essential fungal genes and their use |
| 08/29/2002 | US20020119495 Immunogenic composition of hepatitis C and methods of use thereof |
| 08/29/2002 | US20020119493 Nucleotide sequences coding polypeptides for use in treatment and prevention of cell proliferative defects |
| 08/29/2002 | US20020119491 Monitoring therapeutic levels of S-adenosylmethionine in fluid sample; obtain sample containing enzymatic polypeptides and glycine, measure concentration of preferential reaction products compare to s-adenosylmethionine |
| 08/29/2002 | US20020119489 Butyrylcholinesterase variants and methods of use |
| 08/29/2002 | US20020119487 Human stem cell antigen 2 |
| 08/29/2002 | US20020119464 Compositions and methods enabling a totally internally controlled amplification reaction |
| 08/29/2002 | US20020119460 Prostate cancer gene |
| 08/29/2002 | US20020119440 Peripheral nerve type sodium channels |
| 08/29/2002 | US20020119305 Controlled release composition |
| 08/29/2002 | US20020119202 For therapy of cancer and other angiogenic-dependent diseases |
| 08/29/2002 | US20020119190 Oil-free pharmaceutical compositions containing cyclosporin A |
| 08/29/2002 | US20020119189 Nucleosome-based anti-tumor compositions |
| 08/29/2002 | US20020119167 Human adamts-1 protein, gene coding the same, pharmaceutical composition, and method for immunologically assaying human adamts-1 protein |
| 08/29/2002 | US20020119165 Peptides for inhibition of herpes simplex virus entry |
| 08/29/2002 | US20020119159 Administering to a mucosal surface inducing antigen and mucosal binding component in unconjugated form for inducing sustained immunological tolerance in an individual to a target antigen |
| 08/29/2002 | US20020119158 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 08/29/2002 | US20020119157 For cancer therapy |
| 08/29/2002 | US20020119156 Polynucleotides and polypeptides which are diagnostic markers for lung cance |
| 08/29/2002 | US20020119155 Protein-protein interactions in neurodegenerative diseases |
| 08/29/2002 | US20020119151 CD154 blockade therapy for therapeutic protein inhibitor syndrome |
| 08/29/2002 | US20020119150 Administering an effective amount of a CD40:CD154 binding interrupter to primate graft recipient for therapy of rejection of tissue graft |
| 08/29/2002 | US20020119149 Multivalent T cell receptor complexes |
| 08/29/2002 | US20020119148 ErbB4 antagonists |
| 08/29/2002 | US20020119146 Administering to the mammal in a suitable regimen an effective amount of insulin and an effective amount of a glucagon-like peptide or glucagon-like peptide amide or its fragment or analogue |
| 08/29/2002 | US20020119144 Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents |
| 08/29/2002 | US20020119143 Antithrombin III for disorders caused by angiogenesis |
| 08/29/2002 | US20020119142 Therapy and prophylaxis of metastasis of cancer cells by administering angiotensin |
| 08/29/2002 | US20020119141 Using enzyme for the manufacture of a medicament to eliminate corneal scar, opacity, and haze |
| 08/29/2002 | US20020119140 For regulation of growth of neurons in the Central Nervous System |
| 08/29/2002 | US20020119138 Diacylglycerol o-acyltransferase 2alpha (DGAT2alpha) |
| 08/29/2002 | US20020119137 Useful in treating metabolic disorders or disorders associated with changes in adipose tissue physiological function or mass |
| 08/29/2002 | US20020119136 Antimicrobial peroxidase compositions |
| 08/29/2002 | US20020119135 For therapy of neurodegenerative diseases characterized by apoptosis, including Parkinson's disease and Alzheimer's disease; blood clots, which left untreated could result in stroke; autoimmune diseasesl; cancer |
| 08/29/2002 | US20020119134 For prophylaxis and therapy of vaginal infections |
| 08/29/2002 | US20020119133 Use of bacterial phage associated lysing enzymes for treating various illnesses |
| 08/29/2002 | US20020119132 Use of bacterial phage associated lysing enzymes for treating various illnesses |
| 08/29/2002 | US20020119131 Use of bacterial phage associated lysing enzymes for treating upper respiratory illnesses |
| 08/29/2002 | US20020119130 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 08/29/2002 | US20020119129 Introducing expression vector into tissue or organ, vector comprising a recombinant nucleic acid molecule comprising a DNA molecule, or a corresponding RNA molecule, to form a non-translatable double-stranded RNA molecule; grafting |
| 08/29/2002 | US20020119128 Graft acceptance through manipulation of thymic regeneration |
| 08/29/2002 | US20020119126 Culturing adipose stromal cells in a medium capable of supporting the growth of fibroblasts and differentiation inducing amounts of beta - glycerophosphate and ascorbic acid and/or ascorbic-2 phosphate |
| 08/29/2002 | US20020119122 Ribavirin-pegylated interferon alfa induction hcv combination therapy |
| 08/29/2002 | US20020119120 Amino acid substitution mutants of interleukin 13 |
| 08/29/2002 | US20020119119 Administering natural killer cell activating cytokine or flavonoid, wherein cytokine is not IL-2 or IFN-alpha; administering histamine or serotonin or H2 receptor agonists to inhibit production or release of hydrogen peroxide |
| 08/29/2002 | US20020119117 Modulated release particles for aerosol delivery |
| 08/29/2002 | US20020119104 Treatment of mucositis |
| 08/29/2002 | US20020119095 Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
| 08/29/2002 | US20020117170 Compositions and methods for the pulmonary delivery of aerosolized macromolecules |
| 08/29/2002 | DE10107707A1 Antagonisten für alpha¶4¶beta¶7¶-Integrin Antagonists of integrin alpha¶4¶beta¶7¶ |
| 08/29/2002 | CA2698079A1 A cell therapy method for the treatment of tumors |
| 08/29/2002 | CA2476397A1 Albumin-based drug delivery system and antimicrobial peptides |
| 08/29/2002 | CA2451089A1 Peptide inhibiting platelet derived growth factor (pdgf-bb) and fibroblast growth factor (bfgf) activity |
| 08/29/2002 | CA2442293A1 Zinc finger binding domains for nucleotide sequence ann |
| 08/29/2002 | CA2439235A1 Methods for immuno-detection of epitopes on molecules and for detection of interactions of molecules via fluorescent dyes |
| 08/29/2002 | CA2439193A1 Casoase 3 inhibitors |
| 08/29/2002 | CA2438775A1 T cell receptor variants expressed in mesenchymal cells and uses thereof |
| 08/29/2002 | CA2438769A1 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof |
| 08/29/2002 | CA2438754A1 A cell therapy method for the treatment of tumors |
| 08/29/2002 | CA2438750A1 Aminoglycoside treatment for lysosomal storage diseases |
| 08/29/2002 | CA2438740A1 Drug metabolizing enzymes |
| 08/29/2002 | CA2438682A1 Antibodies that bind both bcma and taci |
| 08/29/2002 | CA2438628A1 Artificial proteins with reduced immunogenicity |
| 08/29/2002 | CA2438518A1 Method of treating neurological diseases |
| 08/29/2002 | CA2438513A1 Modified anti-egfr antibodies with reduced immunogenicity |
| 08/29/2002 | CA2438369A1 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade |
| 08/29/2002 | CA2438235A1 Neurotransmission-associated proteins |
| 08/29/2002 | CA2437529A1 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 08/29/2002 | CA2436832A1 Crystal form of a cyclic depsipeptide having improved activity |
| 08/29/2002 | CA2436399A1 Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |